ResMed Inc. Q2 FY26 Earnings Analysis

- ResMed anticipates high single-digit revenue growth continuing into FY ’27, with better bottom-line performance supported by strong operating margins. - Device sales growth is expected around mid-single digits, with a focus on driving that from 5% toward 6% or higher through demand generation and improved patient capture and conversion. - Masks and other sales are growing robustly, supported by innovative products like the AirTouch N30i and F30i mask lines at premium pricing. - Expansion of the AirSense 11 device platform into Latin America, China, Asia Pacific (Korea, Australia, New Zealand, Singapore), drives growth in those markets. - The Noctrix Health acquisition adds faster-growing, higher-margin revenue in Restless Leg Syndrome, with efforts to increase market access and reimbursement. - Longer-term tailwinds expected from broader patient populations due to GLP-1 oral medications increasing diagnostic funnel sizes and CPAP demand over 1- to 5-year horizons. - Continued investment in R&D and tuck-in acquisitions supports sustained innovation and growth.

- ResMed expects high single-digit revenue growth going into FY ’27 and through 2030. - Operating margins are strong; top-line growth will translate into bottom-line improvements. - Gross margins expected to continue expanding with double-digit basis points improvements annually through 2030. - Operating margin improved to 36.7% this quarter, up from 34.4% last year. - EPS growth was 21% year-over-year this quarter. - Noctrix Health acquisition expected to slightly reduce non-GAAP EPS by $0.02 in Q4 FY ’26. - Continued investment in R&D and marketing to support growth without compromising profitability. - Focus on faster time-to-market for new products and digital/hardware upgrades to drive revenue. - Retirements and leadership transitions planned without disrupting financial discipline or growth trajectory.

- ResMed plans to continue investing in growth through R&D and tuck-in acquisitions. - Capital expenditure for the quarter was $34 million. - The company emphasizes strategic acquisitions, e.g., the upcoming acquisition of Noctrix Health for $340 million, expected to close June 1, 2026, adding a novel product line. - Noctrix investment includes further R&D and sales/marketing spend. - Share buyback programs: repurchased approx. 673,000 shares for $175 million in the last quarter and plans to purchase at least that value again in Q4 FY26. - ResMed is focused on supply chain optimization initiatives to offset cost inflation and improve gross margins. - No specific new large-scale capital projects mentioned, but ongoing investment in technology/platform upgrades (e.g., AirSense 11 expansion), digital health ecosystems, and product innovations.

- There is no mention of current or planned new fundraising through debt or equity in the provided transcript. - The company maintains a strong balance sheet with $1.7 billion cash and $664 million gross debt, resulting in $996 million net cash as of March 31. - They continue to generate robust operating cash flows and plan to invest in growth via R&D and tuck-in acquisitions, suggesting reliance on internal funds. - The company is conducting share buybacks ($175 million repurchased this quarter and plans for at least that amount next quarter) and paying dividends ($0.60 per share quarterly). - No new equity or debt offerings are indicated; focus remains on disciplined capital management and organic growth supplemented by strategic acquisitions like Noctrix Health.

The provided pages from the PDF do not include specific details or figures about the current or expected order book or pending orders for ResMed. Key points related to product demand and sales include: - Strong product performance for new masks like N30i, F30i Comfort, and F30i Clear with premium pricing. - Continued device growth in U.S. (~6% growth in devices), and expansion in Latin America, China, Korea, Australia, New Zealand, and Singapore. - Emphasis on speeding time to market for new products and algorithm upgrades. - No explicit mention or quantification of order backlog or pending orders. - Focus on driving top-line growth and maintaining operating margins to convert revenue into bottom-line improvements. - High single-digit revenue growth guidance maintained for FY '27. No concrete current or expected order book or pending orders data was disclosed in the discussed transcript.